Published on 24/12/2025

Risk Based GMP Compliance Approach in 2023

As the landscape of veterinary product regulations evolves, the need to adopt a risk-based approach to Good Manufacturing Practice (GMP) compliance becomes increasingly critical. This comprehensive tutorial aims to elucidate the principles and implementation of a risk-based GMP compliance framework for the veterinary sector, with emphasis on key regulatory bodies including the FDA’s Center for Veterinary Medicine (CVM), EMA for animal health products, and the expectations of other international regulatory agencies. Our focus is directed towards veterinary GMP compliance consulting services applicable in the U.S., U.K., and across the EU.

Understanding Risk-Based GMP Compliance

The risk-based GMP (Good Manufacturing Practice) compliance approach is instrumental in ensuring that veterinary products are consistently produced and controlled to the quality standards appropriate for their intended use. It acknowledges that not all manufacturing processes and product types carry the same level of risk. As such, it allows for a more flexible response to compliance issues based on the identified risk level.

Rather than applying a one-size-fits-all method, the risk-based GMP compliance framework requires organizations to engage in continuous risk assessment, prioritizing resources where they can achieve the most significant impact on product quality and safety.

In 2023, both the FDA CVM and EMA veterinary guidelines emphasize the necessity of adopting a risk-based approach. For example, the FDA utilizes the principles laid out in Guidance for Industry: Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations, which provides foundational thinking for veterinary practices.

Step 1: Establishing the Risk Management Framework

The first step in implementing a risk-based GMP compliance approach is to establish a robust risk management framework. This framework should adhere to the guidelines set by the ICH Q9 document on Quality Risk Management. Establishing the framework includes the following actions:

• Define the scope: Clearly specify which manufacturing processes, products, and quality attributes are to be assessed. This should encompass all aspects of production, from raw material sourcing to final product release.
• Identify key stakeholders: Involve personnel across various departments including quality assurance, regulatory affairs, manufacturing, and supply chain management, to create a well-rounded perspective.
• Documentation: Create comprehensive documentation outlining the objectives, processes, and key metrics for evaluating risks related to GMP compliance.

These initial steps create the foundation that can support a thorough and systematic evaluation of risks associated with veterinary product manufacturing.

Step 2: Conducting a Risk Assessment

A vital part of the risk-based GMP compliance approach is conducting a detailed risk assessment. This assessment should consist of the following key components:

• Hazard identification: Identify potential hazards that could affect product quality, safety, and efficacy. This includes biological, chemical, and physical hazards related to the manufacturing process.
• Risk analysis: Evaluate identified hazards based on the likelihood of occurrence and potential impact on product quality. Evaluate existing controls and determine the effectiveness of these measures in mitigating identified risks.
• Risk evaluation: Prioritize risks based on their analysis. Risks with a higher chance of occurring and severe impacts should be classified as high-priority risks requiring immediate attention.

During this process, regulatory expectations, such as those outlined by the EMA and FDA, should guide risk criteria and thresholds. Employing tools such as Failure Mode and Effects Analysis (FMEA) and Hazard Analysis and Critical Control Points (HACCP) can facilitate thorough examination.

Step 3: Development of Risk Control Measures

Once risks are identified and prioritized, organizations must develop appropriate risk control measures. This includes:

• Implementation of controls: Based on identified risks, designed controls should include preventive measures, corrective actions, and adequate monitoring systems. Controls must be evidence-based and aligned with both local and international compliance requirements.
• Documentation of measures: All risk control measures should be documented comprehensively, explaining their intended purposes, the operations they affect, and the ways in which their effectiveness will be assessed.
• Training: Employees must be trained on the new risk control measures, processes, and expectations, ensuring alignment from all aspects of the organization.

Proactive risk controls ensure compliance with regulatory requirements while aiding in the mitigation of potential quality issues. It is crucial to incorporate these measures in training programs, enabling continuous improvement and regulatory adherence.

Step 4: Monitoring and Review of Risk Management Strategies

Continuous monitoring and review are essential components of the risk-based GMP approach. This involves:

• Regular audits: Conducting periodic internal audits to assess the effectiveness of risk controls implemented, ensuring that they meet the adequacy of regulatory requirements.
• Feedback loops: Establishing systems for receiving feedback on the efficacy of controls and risk management strategies from personnel across departments.
• Reviewing and updating risk assessments: Regularly updating risk assessments to reflect new knowledge, changes in operations, or regulatory requirements, ensuring that the GMP approach remains relevant and effective.

Regulatory guidelines, such as those from the FDA, emphasize the importance of such reviews. By systematically evaluating risk controls, organizations can remain compliant and responsive to both internal and external challenges.

Step 5: Engaging with Regulatory Authorities

Effective communication with regulatory authorities is paramount in ensuring that the risk-based GMP compliance approach aligns with the expectations of local and international bodies. This includes:

• Pro-active communication: Engage with regulatory agencies such as the FDA CVM or the EMA early in the product development process. Present data and processes that align with risk-based strategies to foster credibility.
• Participation in consultations: Take advantage of formal consultations offered by regulatory agencies to obtain feedback on your risk assessment and control strategies.
• Consideration of global regulatory trends: Stay informed about the evolving regulatory environment and incorporate changes into your compliance strategy accordingly.

Maintaining open channels of dialogue not only aids in meeting regulatory expectations but also assists in building trust and a solid working relationship with authorities that oversee veterinary product registrations.

Conclusion

The implementation of a risk-based GMP compliance approach in veterinary product manufacturing is essential to ensure the safety and efficacy of animal health products. By adopting this framework, organizations can prioritize quality operations, align with regulatory expectations, and ultimately enhance their competitive positioning within the industry.

Through systematic risk assessment, development of risk control measures, and active engagement with authorities, stakeholders can achieve compliance that is both effective and sustainable in the long run. As we progress through 2023, organizations must continue to adapt and refine their approaches, leveraging consultancy services when needed. Veterinary GMP compliance consulting services available can offer additional support to ensure compliance strategies are robust and aligned with applicable regulatory requirements.

For more information regarding veterinary GMP compliance and updates on regulatory frameworks, please refer to resources from the FDA CVM or the EMA for veterinary products.